HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company advancing precision medicine through its transcriptome-wide technology, today announced that it will report its financial results for the third quarter ended September 30, 2021 after the market close on Wednesday, November 10, 2021
TUCSON, Ariz., Nov. 02, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company advancing precision medicine through its transcriptome-wide technology, today announced that it will report its financial results for the third quarter ended September 30, 2021 after the market close on Wednesday, November 10, 2021. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30 pm ET.
| Conference Call & Webcast Details | |
| Date: | Wednesday, November 10 |
| Time: | 4:30 pm ET |
| Toll Free: | 877-407-0789 |
| International: | 201-689-8562 |
| Conference ID: | 13723995 |
| Webcast: | https://78449.themediaframe.com/dataconf/productusers/vvdb/mediaframe/46912/indexl.html |
About HTG:
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.
Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.
Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com
